<DOC>
	<DOCNO>NCT01399697</DOCNO>
	<brief_summary>This randomize , double-blind , parallel-group study evaluate efficacy safety RoActemra/Actemra ( tocilizumab ) combination methotrexate versus RoActemra/Actemra monotherapy patient rheumatoid arthritis inadequate response methotrexate . All patient receive RoActemra/Actemra 8 mg/kg intravenously ( iv ) every 4 week plus oral methotrexate 16 week . Patients achieve low disease activity Week 16 randomize receive 12 week RoActemra/Actemra treatment plus either methotrexate placebo . Anticipated time study treatment 28 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Combination With Methotrexate Versus RoActemra/Actemra Monotherapy Patients With Rheumatoid Arthritis Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Active moderate severe rheumatoid arthritis ( DAS28 &gt; /= 3.2 ) baseline Currently receive methotrexate least 12 week , stable oral dose least 15 mg/week least 6 week prior treatment ( Day 1 ) Body weight &lt; 150 kg Oral corticoid must stable dose least 25 28 day prior baseline ; maximum dose 10 mg/day Pregnant nursing woman Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month baseline Rheumatic autoimmune disease RA Functional class IV define American College Rheumatology ( ACR ) Classification Functional Status Rheumatoid Arthritis Prior history current inflammatory joint disease RA Treatment biologic agent time prior baseline Treatment traditional DMARDs methotrexate within 1 month ( leflunomide 3 month ) prior baseline Intraarticular parenteral corticosteroid within 6 week prior baseline Previous treatment RoActemra/Actemra History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Known active current history recurrent infection History currently active primary secondary immunodeficiency Active tuberculosis require treatment within previous 3 year Positive HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>